Protein Summary
Filament-forming cytoskeletal GTPase. Required for normal organization of the actin cytoskeleton. Involved in cytokinesis. May play a role in HCV RNA replication. Forms a filamentous structure with SEPT12, SEPT6, SEPT2 and probably SEPT4 at the sperm annulus which is required for the structural integrity and motility of the sperm tail during postmeiotic differentiation (PubMed:25588830). This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined. [provided by RefSeq, Jul 2008]
- ENST00000343984
- ENSP00000341524
- ENSG00000125354
- ENST00000354228
- ENSP00000346169
- ENST00000360156
- ENSP00000353278
- ENST00000394610
- ENSP00000378108
- ENST00000460411
- ENSP00000435818
- ENST00000489216
- ENSP00000418715
- KIAA0128
- SEP2
- SEP2
- SEPT2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
transcription factor perturbation | 1 | ||
kinase perturbation | 0.95 | ||
disease perturbation | 0.9 | ||
cellular component | 0.86 | ||
molecular function | 0.76 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 168.34 (req: < 5)
Gene RIFs: 21 (req: <= 3)
Antibodies: 264 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 168.34 (req: >= 5)
Gene RIFs: 21 (req: > 3)
Antibodies: 264 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 9
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0